NO20073814L - GLP-1-agonister, sammensetninger, fremgangsmater og anvendelser - Google Patents
GLP-1-agonister, sammensetninger, fremgangsmater og anvendelserInfo
- Publication number
- NO20073814L NO20073814L NO20073814A NO20073814A NO20073814L NO 20073814 L NO20073814 L NO 20073814L NO 20073814 A NO20073814 A NO 20073814A NO 20073814 A NO20073814 A NO 20073814A NO 20073814 L NO20073814 L NO 20073814L
- Authority
- NO
- Norway
- Prior art keywords
- glp
- methods
- mimetibody
- agonist
- compositions
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63831304P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/046602 WO2007046834A2 (en) | 2004-12-22 | 2005-12-22 | Glp-1 agonists, compositions, methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073814L true NO20073814L (no) | 2007-09-14 |
Family
ID=37962937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073814A NO20073814L (no) | 2004-12-22 | 2007-07-20 | GLP-1-agonister, sammensetninger, fremgangsmater og anvendelser |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070128193A1 (enExample) |
| EP (1) | EP1843788A4 (enExample) |
| JP (1) | JP2008525477A (enExample) |
| KR (1) | KR20070090036A (enExample) |
| CN (1) | CN101415439A (enExample) |
| AU (1) | AU2005337493A1 (enExample) |
| BR (1) | BRPI0519241A2 (enExample) |
| CA (1) | CA2592065A1 (enExample) |
| CR (1) | CR9266A (enExample) |
| EA (1) | EA200701362A1 (enExample) |
| IL (1) | IL183940A0 (enExample) |
| MX (1) | MX2007007602A (enExample) |
| NI (1) | NI200700158A (enExample) |
| NO (1) | NO20073814L (enExample) |
| SG (1) | SG158158A1 (enExample) |
| WO (1) | WO2007046834A2 (enExample) |
| ZA (1) | ZA200706030B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| DK2314298T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Microparticles comprising diketopiperazinsalte for drug delivery |
| JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Ｇｌｐ−１分子と制吐剤との医薬製剤 |
| BRPI0616071B8 (pt) | 2005-09-14 | 2021-05-25 | Mannkind Corp | métodos de revestir uma micropartícula cristalina pré-formada em suspensão com um agente ativo |
| WO2007081654A2 (en) * | 2005-12-28 | 2007-07-19 | Zoltan Laboratories Llc | Compositions and methods to enhance viability and function of islet cells |
| IN2015DN00888A (enExample) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| TW200843794A (en) * | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| WO2008092209A1 (en) * | 2007-02-01 | 2008-08-07 | Arana Therapeutics Limited | Protein construct with improved properties |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| TWI592178B (zh) | 2008-06-13 | 2017-07-21 | 曼凱公司 | 用於藥物傳輸之乾粉吸入器及系統 |
| MX2010014240A (es) | 2008-06-20 | 2011-03-25 | Mankind Corp | Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion. |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US20110020392A1 (en) * | 2008-10-14 | 2011-01-27 | Salubrious Pharmaceutical, Llc | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| EP3677275B1 (de) | 2008-10-17 | 2024-06-12 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| US8748377B2 (en) | 2008-12-10 | 2014-06-10 | Glaxosmithkline Llc | Pharmaceutical compositions |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| TWI547487B (zh) | 2009-06-12 | 2016-09-01 | 曼凱公司 | 具限定比表面積之二酮基哌微粒子 |
| CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| ES2965209T3 (es) | 2009-11-13 | 2024-04-11 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina |
| US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用 |
| JP2014502984A (ja) * | 2011-01-19 | 2014-02-06 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物 |
| US8925726B2 (en) | 2011-04-01 | 2015-01-06 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| US9950038B2 (en) * | 2011-08-05 | 2018-04-24 | The Trustees Of The Universiy Of Pennsylvania | Methods and compositions for inhibiting delayed graft function |
| TWI608847B (zh) | 2011-08-29 | 2017-12-21 | 賽諾菲阿凡提斯德意志有限公司 | 用於控制糖尿病二型病患血糖的醫藥組合物 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
| EP2780031B1 (en) | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| CA2864655A1 (en) * | 2012-03-01 | 2013-09-06 | Yeda Research And Development Co. Ltd. | Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
| ES2624294T3 (es) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Sistemas de suministro de fármacos en polvo seco |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| KR102246914B1 (ko) | 2013-03-15 | 2021-04-30 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
| ES2709339T3 (es) | 2013-04-03 | 2019-04-16 | Sanofi Sa | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada |
| MX375448B (es) | 2013-07-18 | 2025-03-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP3289074B1 (en) * | 2015-04-28 | 2023-10-04 | Université de Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
| CN105504026B (zh) * | 2015-12-24 | 2018-12-07 | 广东医科大学 | 一种pac1-r和glp-1r的双向激动剂ot23及应用 |
| WO2017211321A1 (zh) * | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| US20230183335A1 (en) | 2020-06-03 | 2023-06-15 | Københavns Universitet | Glp1r agonist nmdar antagonist conjugates |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| NZ525577A (en) * | 2000-12-07 | 2005-05-27 | Lilly Co Eli | Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus |
| US20020187926A1 (en) * | 2001-03-07 | 2002-12-12 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
| AU2003256336A1 (en) * | 2002-06-28 | 2004-01-19 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| AU2005231359A1 (en) * | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human GLP-1 mimetibodies, compositions, methods and uses |
-
2005
- 2005-12-22 CA CA002592065A patent/CA2592065A1/en not_active Abandoned
- 2005-12-22 MX MX2007007602A patent/MX2007007602A/es not_active Application Discontinuation
- 2005-12-22 CN CNA2005800484969A patent/CN101415439A/zh active Pending
- 2005-12-22 WO PCT/US2005/046602 patent/WO2007046834A2/en not_active Ceased
- 2005-12-22 EA EA200701362A patent/EA200701362A1/ru unknown
- 2005-12-22 AU AU2005337493A patent/AU2005337493A1/en not_active Abandoned
- 2005-12-22 JP JP2007548473A patent/JP2008525477A/ja active Pending
- 2005-12-22 US US11/315,728 patent/US20070128193A1/en not_active Abandoned
- 2005-12-22 BR BRPI0519241-2A patent/BRPI0519241A2/pt not_active Application Discontinuation
- 2005-12-22 SG SG200908512-7A patent/SG158158A1/en unknown
- 2005-12-22 KR KR1020077016979A patent/KR20070090036A/ko not_active Withdrawn
- 2005-12-22 EP EP05858658A patent/EP1843788A4/en not_active Withdrawn
-
2007
- 2007-06-14 IL IL183940A patent/IL183940A0/en unknown
- 2007-06-19 NI NI200700158A patent/NI200700158A/es unknown
- 2007-07-20 NO NO20073814A patent/NO20073814L/no not_active Application Discontinuation
- 2007-07-20 CR CR9266A patent/CR9266A/es not_active Application Discontinuation
- 2007-07-20 ZA ZA200706030A patent/ZA200706030B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008525477A (ja) | 2008-07-17 |
| CN101415439A (zh) | 2009-04-22 |
| IL183940A0 (en) | 2007-10-31 |
| SG158158A1 (en) | 2010-01-29 |
| AU2005337493A1 (en) | 2007-04-26 |
| CR9266A (es) | 2008-09-09 |
| KR20070090036A (ko) | 2007-09-04 |
| CA2592065A1 (en) | 2007-04-26 |
| ZA200706030B (en) | 2009-12-30 |
| WO2007046834A2 (en) | 2007-04-26 |
| NI200700158A (es) | 2008-05-13 |
| EP1843788A2 (en) | 2007-10-17 |
| MX2007007602A (es) | 2007-12-07 |
| EA200701362A1 (ru) | 2008-08-29 |
| BRPI0519241A2 (pt) | 2009-01-06 |
| EP1843788A4 (en) | 2009-11-18 |
| US20070128193A1 (en) | 2007-06-07 |
| WO2007046834A3 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073814L (no) | GLP-1-agonister, sammensetninger, fremgangsmater og anvendelser | |
| NO20064953L (no) | Human GLP-1 mimetilegemer, sammensetninger, fremgangsmater og anvendelser | |
| NO20090780L (no) | Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser | |
| NO20061931L (no) | Humane EPO-mimetlsk hengselkjerne-etterlignere, sammensetninger, fremgangsmater og anvendelser | |
| NO20076024L (no) | Anti-IL-6 antistoffer, sammensetninger, fremgangsmater og anvendelser | |
| MX2009006892A (es) | Uso de agonistas del receptor de peptido similar al glucagon de tipo 1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles de lipidos. | |
| NO20076563L (no) | Anti- MCP-1 antistoffer, sammensetninger og anvendelser | |
| MX2009005901A (es) | Nuevos polipeptidos cristalinos de bacillus thuringiensis, polinucleotidos y composiciones de los mismos. | |
| MX2017004814A (es) | Polipeptidos insecticidas que tienen un espectro de actividad mejorado y sus usos. | |
| UA105046C2 (uk) | Пестицидний ген axmi-205 та його використання для захисту рослин від комах-шкідників | |
| MX2010004179A (es) | Anticuerpos anti-amiloide, composiciones, metodos y usos. | |
| ATE469897T1 (de) | Indazolcarbonsäureamidverbindungen | |
| WO2008060669A3 (en) | Vaccine for avian influenza and methods of use | |
| NO20090596L (no) | Antivirale fosfinatforbindelser | |
| TNSN07087A1 (en) | Stable liquid formulations of plasmid dna | |
| DK1853111T3 (da) | Fluegellokkemad | |
| AR070143A1 (es) | Gen de bacillus thuringiensis (bt) con actividad contra coleopteros | |
| BRPI0409871A (pt) | promotores tecido-especìficos | |
| NO20075272L (no) | Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser | |
| AR070146A1 (es) | Gen de bacillus thuringiensis (bt) con actividad contra coleopteros | |
| ATE472316T1 (de) | Haarbehandlungszusammensetzungen | |
| DK1476012T3 (da) | Transgene mus, der udtrykker PRKAG3 | |
| WO2007076319A3 (en) | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses | |
| WO2010039510A3 (en) | Use of syndyphalin-33 (sd-33; try-dmet(o)-gly-methylphenylethylamide) as a therapeutic agent to enhance the health and well-being of newly-weaned animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |